9 Meters Biopharma Debt to Equity

9 Meters Biopharma (NMTR) currently reports a debt-to-equity ratio of -0.82. That is below the Technology sector average of 0.4. Use the charts on this page to explore 9 Meters Biopharma's debt-to-equity ratio history and peer comparisons.

9 Meters Biopharma's debt-to-equity ratio of -0.82 is lower than the Technology sector average of 0.4. That is roughly 304.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates 9 Meters Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At -0.82, NMTR can look expensive or cheap only in context — versus its own history, growth rate, and Technology peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -0.82, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 0.4. From there, open related valuation or income-statement pages for 9 Meters Biopharma, and consider following NMTR for alerts when major investors trade the stock.

9 Meters Biopharma is classified in the Technology sector. On debt-to-equity ratio, it currently shows -0.82 versus a sector average near 0.4. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing NMTR with unrelated industries.